The Experts below are selected from a list of 6105 Experts worldwide ranked by ideXlab platform
Dincer Firat - One of the best experts on this subject based on the ideXlab platform.
-
Acute Tumor Lysis Syndrome following intrathecal methotrexate.
Leukemia & lymphoma, 1996Co-Authors: Mustafa Benekli, Ibrahim Gullu, Abdurrahman Kadayifci, Gülten Tekuzman, Dincer FiratAbstract:We report a 17-year-old boy with meningeal involvement of lymphoblastic lymphoma who experienced acute Tumor Lysis Syndrome following intrathecal administration of methotrexate. Intrathecally injected methotrexate provides a slow- release reservoir of methotrexate into the bloodstream with prolonged cy totoxic levels. To the best of our knowledge, this is the second case of Tumor Lysis Syndrome to be described after intrathecal methotrexate injection. The pathogenesis of this unusual complication of intrathecal chemotherapy is discussed.
Dubashi Biswajit - One of the best experts on this subject based on the ideXlab platform.
-
Tumor Lysis Syndrome in multiple myeloma treated with bortezomib.
Journal of pharmacology & pharmacotherapeutics, 2014Co-Authors: Km Dhanraj, Dubashi BiswajitAbstract:A 65 year old male diagnosed as multiple myeloma was started on bortezomib developed Tumor Lysis Syndrome. Bortezomib induced Tumor Lysis is rare and suitable precautions should be considered in these patients.
Mustafa Benekli - One of the best experts on this subject based on the ideXlab platform.
-
Acute Tumor Lysis Syndrome following intrathecal methotrexate.
Leukemia & lymphoma, 1996Co-Authors: Mustafa Benekli, Ibrahim Gullu, Abdurrahman Kadayifci, Gülten Tekuzman, Dincer FiratAbstract:We report a 17-year-old boy with meningeal involvement of lymphoblastic lymphoma who experienced acute Tumor Lysis Syndrome following intrathecal administration of methotrexate. Intrathecally injected methotrexate provides a slow- release reservoir of methotrexate into the bloodstream with prolonged cy totoxic levels. To the best of our knowledge, this is the second case of Tumor Lysis Syndrome to be described after intrathecal methotrexate injection. The pathogenesis of this unusual complication of intrathecal chemotherapy is discussed.
Km Dhanraj - One of the best experts on this subject based on the ideXlab platform.
-
Tumor Lysis Syndrome in multiple myeloma treated with bortezomib.
Journal of pharmacology & pharmacotherapeutics, 2014Co-Authors: Km Dhanraj, Dubashi BiswajitAbstract:A 65 year old male diagnosed as multiple myeloma was started on bortezomib developed Tumor Lysis Syndrome. Bortezomib induced Tumor Lysis is rare and suitable precautions should be considered in these patients.
Muhammad Asad Maqbool - One of the best experts on this subject based on the ideXlab platform.
-
Sorafenib-induced Tumor Lysis Syndrome in a patient with metastatic hepatocellular carcinoma
Hematology oncology and stem cell therapy, 2018Co-Authors: Sardar Zakariya Imam, Mohammad Faizan Zahid, Muhammad Asad MaqboolAbstract:Abstract Tumor Lysis Syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal Tumor Lysis Syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, Tumor Lysis Syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated.
